INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›health›Povorcitinib Improves Clinical Response in Moderate-to-Severe Hidradenitis Suppurativa
health

Povorcitinib Improves Clinical Response in Moderate-to-Severe Hidradenitis Suppurativa

By Info60 US Desk•Summary of reporting by Health Management Professionals Global Learning Ne•18h ago•0 views•
Once-daily oral povorcitinib significantly improved clinical response compared with placebo in patients with moderate-to-severe hidradenitis suppurativa, with consistent findings across 2 phase 3 trials.
ONLY AVAILABLE IN PAID PLANS
Read Full Article

Share this story

Report an error

Up next

Related Stories

Could humanoid robot soldiers be on the horizon?

Could humanoid robot soldiers be on the horizon?

nbcnews.com

Astoria Runner On Team ALZ

Astoria Runner On Team ALZ

Queens Gazette

Pete Davidson opens up on his ‘huge problem’ with drugs and why he got sober

Pete Davidson opens up on his ‘huge problem’ with drugs and why he got sober

Marin Independent Journal

$14 million outpatient facility coming to Moulton

$14 million outpatient facility coming to Moulton

Decatur Daily

Damien Center Launches New Flex Program

Weeklyview

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!